title: Non-cardiac surgery in patients with coronary stents: the RECO study.
abstract: BACKGROUND
  Interruption or maintenance of oral antiplatelet therapy (OAT) during an invasive procedure may result in ischaemic and/or haemorrhagic complications. There is currently a lack of clear guidance regarding the issue of treatment interruption during surgical procedures.
  
  
  OBJECTIVE
  To evaluate the rate of major adverse cardiac and cerebrovascular events (MACCEs) and major or minor bleeding complications and their associated independent correlates in coronary stented patients undergoing urgent or planned non-cardiac surgery.
  
  
  METHODS
  Prospective, multicentre, observational cohort study of 1134 consecutive patients with coronary stents.
  
  
  METHODS
  The co-primary endpoints consisted of the incidence of MACCE and major bleeding within the first 30 days of an invasive procedure.
  
  
  RESULTS
  MACCE and haemorrhagic complications were observed in 124 (10.9%) and 108 (9.5%) patients, respectively, within an average time delay from invasive procedure to event of 3.3±3.9 and 5.3±5.3 days. Independent preoperative correlates for MACCE were complete OAT interruption for more than 5 days prior to surgery, preoperative haemoglobin <10 g/dl, creatinine clearance of <30 ml/min and emergency or high-risk surgery. Independent factors for haemorrhagic complications were preoperative haemoglobin <10 g/dl, creatinine clearance between 30 and 60 ml/min, a delay from stent implantation to surgery <3 months and high-risk surgery according to the Lee classification.
  
  
  CONCLUSIONS
  Patients with coronary stents undergoing an invasive procedure are at high risk of perioperative myocardial infarction including stent thrombosis irrespective of the stent type and major bleeding. Interruption of OAT more than 5 days prior to an invasive procedure is a key player for MACCE.
  
  
  BACKGROUND
  NCT01045850.
authors.affiliation: Department of Anaesthesia and Intensive Care Medicine, Grenoble University Hospital, Grenoble, France. palbaladejo@chu-grenoble.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Albaladejo
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Marret
authors.forename: Charles-Marc
authors.initials: CM
authors.lastname: Samama
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Collet
authors.forename: Kou
authors.initials: K
authors.lastname: Abhay
authors.forename: Olivier
authors.initials: O
authors.lastname: Loutrel
authors.forename: Hélène
authors.initials: H
authors.lastname: Charbonneau
authors.forename: Samir
authors.initials: S
authors.lastname: Jaber
authors.forename: Sophie
authors.initials: S
authors.lastname: Thoret
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Bosson
authors.forename: Vincent
authors.initials: V
authors.lastname: Piriou
mesh_terms: D000284:Administration, Oral; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000209:etiology; D016009:Chi-Square Distribution; D000077144:Clopidogrel; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005602:France; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D019106:Postoperative Hemorrhage / Q000139:chemically induced; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents; D013514:Surgical Procedures, Operative / Q000009:adverse effects*; D013927:Thrombosis / Q000209:etiology; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin